JP7010812B2 - Ｆｃ含有タンパク質の発現 - Google Patents

Ｆｃ含有タンパク質の発現 Download PDF

Info

Publication number
JP7010812B2
JP7010812B2 JP2018514955A JP2018514955A JP7010812B2 JP 7010812 B2 JP7010812 B2 JP 7010812B2 JP 2018514955 A JP2018514955 A JP 2018514955A JP 2018514955 A JP2018514955 A JP 2018514955A JP 7010812 B2 JP7010812 B2 JP 7010812B2
Authority
JP
Japan
Prior art keywords
cpd
host cell
gene
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018514955A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529341A5 (enExample
JP2018529341A (ja
Inventor
ベンジャミン ヘイリー，
チーラン フー，
ジョン シー． ジョリー，
エイミー ワイ． シェン，
ブラッドリー リチャード スネデカー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2018529341A publication Critical patent/JP2018529341A/ja
Publication of JP2018529341A5 publication Critical patent/JP2018529341A5/ja
Priority to JP2022003590A priority Critical patent/JP7493540B2/ja
Application granted granted Critical
Publication of JP7010812B2 publication Critical patent/JP7010812B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018514955A 2015-09-22 2016-09-21 Ｆｃ含有タンパク質の発現 Active JP7010812B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022003590A JP7493540B2 (ja) 2015-09-22 2022-01-13 Ｆｃ含有タンパク質の発現

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222187P 2015-09-22 2015-09-22
US62/222,187 2015-09-22
PCT/US2016/052962 WO2017053482A1 (en) 2015-09-22 2016-09-21 Expression of fc-containing proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022003590A Division JP7493540B2 (ja) 2015-09-22 2022-01-13 Ｆｃ含有タンパク質の発現

Publications (3)

Publication Number Publication Date
JP2018529341A JP2018529341A (ja) 2018-10-11
JP2018529341A5 JP2018529341A5 (enExample) 2019-11-07
JP7010812B2 true JP7010812B2 (ja) 2022-02-10

Family

ID=57068227

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018514955A Active JP7010812B2 (ja) 2015-09-22 2016-09-21 Ｆｃ含有タンパク質の発現
JP2022003590A Active JP7493540B2 (ja) 2015-09-22 2022-01-13 Ｆｃ含有タンパク質の発現

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022003590A Active JP7493540B2 (ja) 2015-09-22 2022-01-13 Ｆｃ含有タンパク質の発現

Country Status (12)

Country Link
US (3) US11591382B2 (enExample)
EP (2) EP3699269A1 (enExample)
JP (2) JP7010812B2 (enExample)
KR (1) KR102645625B1 (enExample)
CN (1) CN108138147B (enExample)
AU (1) AU2016329001A1 (enExample)
BR (1) BR112018005464A2 (enExample)
CA (1) CA2996691A1 (enExample)
HK (1) HK1255456A1 (enExample)
IL (1) IL257887A (enExample)
MX (1) MX2018003445A (enExample)
WO (1) WO2017053482A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3699269A1 (en) 2015-09-22 2020-08-26 F. Hoffmann-La Roche AG Expression of fc-containing proteins
CN109321570A (zh) * 2017-07-31 2019-02-12 中国科学院上海生命科学研究院 用于体外抗体类型转换的方法及试剂盒
JP2021519073A (ja) 2018-03-29 2021-08-10 ジェネンテック， インコーポレイテッド 哺乳動物細胞におけるラクトジェニック活性の制御
CN112074604A (zh) * 2018-05-04 2020-12-11 西格马-奥尔德里奇有限责任公司 具有修饰的宿主细胞蛋白概况的工程改造的细胞
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
EP4217383A1 (en) 2020-09-22 2023-08-02 Bristol-Myers Squibb Company Methods for producing therapeutic proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130323785A1 (en) 2010-11-04 2013-12-05 Korea Research Institute Of Bioscience And Biotechnology Method for producing human epidermal growth factor in large volume from yeast
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
JP2014526884A (ja) 2011-07-06 2014-10-09 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
WO2000018938A1 (en) 1998-09-29 2000-04-06 Pioneer Hi-Bred International, Inc. Mar/sar elements flanking rsyn7-driven construct
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
WO2002048379A1 (en) 2000-12-15 2002-06-20 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
DK1771482T3 (da) 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
KR20080025174A (ko) * 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
US20100204055A1 (en) 2008-12-05 2010-08-12 Bonner-Ferraby Phoebe W Autoantibody detection systems and methods
ES2550761T3 (es) * 2009-11-25 2015-11-12 Novo Nordisk A/S Método para producción de polipéptidos
DK2729482T3 (en) 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
CN103717729B (zh) * 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
CN106459995B (zh) * 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
KR102170502B1 (ko) * 2013-12-11 2020-10-28 리제너론 파마슈티칼스 인코포레이티드 게놈의 표적화된 변형을 위한 방법 및 조성물
EP3699269A1 (en) 2015-09-22 2020-08-26 F. Hoffmann-La Roche AG Expression of fc-containing proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130323785A1 (en) 2010-11-04 2013-12-05 Korea Research Institute Of Bioscience And Biotechnology Method for producing human epidermal growth factor in large volume from yeast
JP2014526884A (ja) 2011-07-06 2014-10-09 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biotechnol Bioeng., 2008 Aug 15, vol. 100, no. 6, pp. 1132-1143
Biotechnol Bioeng., 2011 Feb, vol. 108, no. 2, pp. 404-412
BIOTECHNOLOGY AND BIOENGINEERING，米国，2016年10月，VOL:113,NR:10，PAGE(S):2100-2106，https://www.semanticscholar.org/paper/Carboxypeptidase-D-is-the-only-enzyme-responsible-Hu-Zhang/dc989820df5a8fe10e9ac59c780f8c262a5da17a
CELL BIOLOGY INTERNATIONAL，英国，2013年04月30日，VOL:37,NR:9，PAGE(S):929-939，https://onlinelibrary.wiley.com/doi/abs/10.1002/cbin.10113

Also Published As

Publication number Publication date
US20180282398A1 (en) 2018-10-04
US11591382B2 (en) 2023-02-28
EP3699269A1 (en) 2020-08-26
US12421299B2 (en) 2025-09-23
IL257887A (en) 2018-05-31
WO2017053482A1 (en) 2017-03-30
KR20180053398A (ko) 2018-05-21
KR102645625B1 (ko) 2024-03-07
CN108138147B (zh) 2022-11-01
MX2018003445A (es) 2018-08-01
CN108138147A (zh) 2018-06-08
HK1255456A1 (zh) 2019-08-16
JP7493540B2 (ja) 2024-05-31
JP2022058603A (ja) 2022-04-12
EP3353288A1 (en) 2018-08-01
CA2996691A1 (en) 2017-03-30
US20260049120A1 (en) 2026-02-19
JP2018529341A (ja) 2018-10-11
BR112018005464A2 (en) 2018-10-09
US20230159625A1 (en) 2023-05-25
AU2016329001A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
JP7493540B2 (ja) Ｆｃ含有タンパク質の発現
US12391769B2 (en) Methods of making fucosylated and afucosylated forms of a protein
US20200032295A1 (en) Methods and products for expressing proteins in cells
JP2021045166A (ja) ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法及び組成物
CN114555634B (zh) 用于扩增调节性t细胞的白介素-2突变蛋白
ES2901128T3 (es) Proteína no fucosilada y métodos de la misma
JP7641233B2 (ja) 改善された遺伝子編集のための組成物及び方法
Mensah et al. Establishment of DHFR-deficient HEK293 cells for high yield of therapeutic glycoproteins
CN118251491A (zh) 用于敲除C5的CRISPR/Cas相关方法及组合物
KR102956080B1 (ko) 분비형 단백질을 생산하기 위한 포유동물 세포
KR20260064747A (ko) 폼페병의 치료를 위한 항-TfR:GAA 및 항-CD63:GAA 삽입
KR20260060472A (ko) 산 스핑고미엘리나아제 결핍 치료용 항-TfR:산 스핑고미엘리나아제
BR112017003074B1 (pt) Vetor, e, métodos de produção de uma proteína recombinante de interesse e de emprego de tunicamicina como um marcador de seleção

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220113

R150 Certificate of patent or registration of utility model

Ref document number: 7010812

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250